Pressure Biosciences

Greetings. Welcome to the Pressure Biosciences Q4 and Fiscal Year 2022 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Richard Schumacher, President and CEO. You may begin.

Thank you, John, and welcome everybody to our fourth quarter and fiscal year 2022 review and business update. Before I begin with the actual call, I need to read a cautionary statement. The following remarks may constitute forward-looking statements within the meaning of the Privacy Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results performance or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, those detailed from time to time in the company's filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements Our statements have been based. So before we begin, I am pleased once again to welcome back to the PBI Financial Review and Business Update two guys who are super important to the company and to the future success of PBI, John Hollister, our Director of Marketing and Sales, and Jeff Peterson, our Board Chairman. Welcome, gentlemen.

My pleasure.